Assembly Biosciences (NASDAQ: ASMB) director receives 8,000 stock options grant

Rhea-AI Filing Summary

Assembly Biosciences director Lisa Johnson-Pratt received a grant of stock options for 8,000 shares of common stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036. They vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting. Following this grant, she holds 8,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Johnson-Pratt Lisa

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	8,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 8,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 8,000 options Exercise price: $24.11 per share Underlying shares: 8,000 shares +2 more

5 metrics

Options granted 8,000 options Stock Option (right to buy) granted to director

Exercise price $24.11 per share Conversion or exercise price of granted options

Underlying shares 8,000 shares Common Stock underlying the options

Expiration date June 4, 2036 Option expiration date

Vesting date trigger Earlier of June 4, 2027 or 2027 annual meeting Vesting condition assuming continuous service

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, vest, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 24.1100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual meeting of stockholders financial

"the date of the Issuer's 2027 annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Johnson-Pratt Lisa

(Last) (First) (Middle)

C/O ASSEMBLY BIOSCIENCES, INC.

TWO TOWER PLACE, 7TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASSEMBLY BIOSCIENCES, INC. [ ASMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$24.11	06/04/2026		A		8,000		(1)	06/04/2036	Common Stock	8,000	$0	8,000	D

Explanation of Responses:

1. Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.

	/s/ John O. Gunderson, as Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ASMB director Lisa Johnson-Pratt report?

Lisa Johnson-Pratt reported a grant of stock options for 8,000 shares. These are derivative securities giving her the right to buy Assembly Biosciences common stock at a fixed price, subject to a vesting schedule and expiration date.

How many Assembly Biosciences (ASMB) options were granted in this Form 4?

The filing reports a grant of 8,000 stock options. Each option relates to one share of Assembly Biosciences common stock, so the award covers 8,000 underlying shares, all held directly by the reporting person after the transaction.

What is the exercise price of the ASMB stock options granted?

The stock options have an exercise price of $24.11 per share. This is the price at which Lisa Johnson-Pratt can purchase Assembly Biosciences common stock once the options vest and before they expire, if she chooses to exercise them.

When do Lisa Johnson-Pratt’s ASMB options vest according to the Form 4?

The options vest upon the earlier of June 4, 2027 or the 2027 annual meeting. Vesting requires continuous service through that date, after which the options become exercisable, subject to their expiration in 2036.

When do the Assembly Biosciences stock options reported in this Form 4 expire?

The options expire on June 4, 2036. After that expiration date, any unexercised options become worthless, so the holder must exercise vested options before or on that date to purchase common shares.

Is the ASMB Form 4 transaction an open-market buy or compensation grant?

The transaction is a compensation-related grant, not an open-market purchase. It is coded as a “Grant, award, or other acquisition” of derivative securities, reflecting options awarded for service rather than shares bought on the market.